Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis

Sophie N.M. Binks; Michele Veldsman; Adam E. Handel; Saiju Jacob; Paul Maddison; Jan Coebergh; Sophia Michael; Sudarshini Ramanathan; Ava Easton; Mette Scheller Nissen; Maria Isabel Leite; David Okai; Morten Blaabjerg; Masud Husain; Sarosh R. Irani

doi:10.1002/acn3.52006

Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis

Sophie N.M. Binks
, Michele Veldsman
, Adam E. Handel
, Saiju Jacob
, Paul Maddison
, Jan Coebergh
, Sophia Michael
, Sudarshini Ramanathan
, Ava Easton
, Mette Scheller Nissen
, Maria Isabel Leite
, David Okai
, Morten Blaabjerg
, Masud Husain
, Sarosh R. Irani^*

^*Kontaktforfatter

University of Oxford
Oxford University Hospitals NHS Foundation Trust
University Hospitals Birmingham NHS Foundation Trust
Queen's Medical Centre
Ashford and St Peter's NHS Hospitals Foundation Trust
The University of Sydney
Concord Repatriation General Hospital
The Encephalitis Society
University of Liverpool
South London and Maudsley NHS Foundation Trust
Mayo Clinic

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

50 Downloads (Pure)

Abstract

Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

Originalsprog	Engelsk
Tidsskrift	Annals of Clinical and Translational Neurology
Vol/bind	11
Udgave nummer	4
Sider (fra-til)	1053-1058
ISSN	2328-9503
DOI	https://doi.org/10.1002/acn3.52006
Status	Udgivet - apr. 2024

Finansiering

SRI is a co‐applicant and receives royalties on patent application WO/2010/046716 (U.K. patent no. PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licenced commercially for the development of assays for LGI1 and other VGKC‐complex antibodies. SRI and SB are co‐applicants on a patent application entitled ‘Diagnostic Strategy to improve specificity of CASPR2 antibody detection’ (PCT/GB2019/051257, publication number WO/2019/211633 and UK1807410.4). SRI has received honoraria from UCB, MedImmun, ADC therapeutics and Medlink Neurology, and research support from CSL Behring, UCB and ONO Pharma. AEH has received research support from UCB Pharma. JC has received speaking honoraria from Bial, Brittania, advisory board fees from Bial and Teva and is on a patent for a test of GABA antibodies. SJ has served as an international advisory board member for Alexion, Alnylam, Argenx, Regeneron, Immunovant and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals and has received speaker fees from Argenx, Eisai, Terumo BCT and UCB pharmaceuticals. SR serves as a consultant on an advisory board for UCB and Limbic Neurology, and has been an invited speaker for Biogen, Alexion, Novartis, Excemed and Limbic Neurology. AE has received no personal honoraria, but The Encephalitis Society has received sponsorship/honoraria/speaker fees from Valneva, Roche, UCB, Pfizer, Biomerieux, CSL Behring, Svar and EuroImmun. MIL has no conflicts of interest relevant to encephalitis. MB has received research support from Aptinyx Inc and honoraria from Medlink Neurology. MH has received fees for a lecture delivered to Lilly UK and for consultancy to Otsuka Pharmaceuticals. MV, PM, SM, MSN and DO have no conflicts of interest to declare. A

Dokumenter og links

10.1002/acn3.52006Licens: CC BY

Open Access VersionForlagets udgivne version, 487 KBLicens: CC BY

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Binks, S. N. M., Veldsman, M., Handel, A. E., Jacob, S., Maddison, P., Coebergh, J., Michael, S., Ramanathan, S., Easton, A., Nissen, M. S., Leite, M. I., Okai, D., Blaabjerg, M., Husain, M., & Irani, S. R. (2024). Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis. Annals of Clinical and Translational Neurology, 11(4), 1053-1058. https://doi.org/10.1002/acn3.52006

@article{384ce07b6d09422583452e79c8104606,

title = "Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis",

abstract = "Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85\% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51\% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.",

keywords = "Autoantibodies, Encephalitis, Fatigue/etiology, Glioma, Humans, Intracellular Signaling Peptides and Proteins, Leucine, Quality of Life",

author = "Binks, \{Sophie N.M.\} and Michele Veldsman and Handel, \{Adam E.\} and Saiju Jacob and Paul Maddison and Jan Coebergh and Sophia Michael and Sudarshini Ramanathan and Ava Easton and Nissen, \{Mette Scheller\} and Leite, \{Maria Isabel\} and David Okai and Morten Blaabjerg and Masud Husain and Irani, \{Sarosh R.\}",

year = "2024",

month = apr,

doi = "10.1002/acn3.52006",

language = "English",

volume = "11",

pages = "1053--1058",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "Wiley",

number = "4",

}

Binks, SNM, Veldsman, M, Handel, AE, Jacob, S, Maddison, P, Coebergh, J, Michael, S, Ramanathan, S, Easton, A, Nissen, MS, Leite, MI, Okai, D, Blaabjerg, M, Husain, M & Irani, SR 2024, 'Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis', Annals of Clinical and Translational Neurology, bind 11, nr. 4, s. 1053-1058. https://doi.org/10.1002/acn3.52006

TY - JOUR

T1 - Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis

AU - Binks, Sophie N.M.

AU - Veldsman, Michele

AU - Handel, Adam E.

AU - Jacob, Saiju

AU - Maddison, Paul

AU - Coebergh, Jan

AU - Michael, Sophia

AU - Ramanathan, Sudarshini

AU - Easton, Ava

AU - Nissen, Mette Scheller

AU - Leite, Maria Isabel

AU - Okai, David

AU - Blaabjerg, Morten

AU - Husain, Masud

AU - Irani, Sarosh R.

PY - 2024/4

Y1 - 2024/4

N2 - Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

AB - Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

KW - Autoantibodies

KW - Encephalitis

KW - Fatigue/etiology

KW - Glioma

KW - Humans

KW - Intracellular Signaling Peptides and Proteins

KW - Leucine

KW - Quality of Life

U2 - 10.1002/acn3.52006

DO - 10.1002/acn3.52006

M3 - Journal article

C2 - 38303486

AN - SCOPUS:85184160354

SN - 2328-9503

VL - 11

SP - 1053

EP - 1058

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 4

ER -

Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis

Abstract

Finansiering

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater